- Home
- DRTS vs HQL Comparison
DRTS vs HQL Comparison
Compare DRTS & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DRTS | HQL |
|---|---|---|
| Founded | 2015 | 1992 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 445.1M | 510.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DRTS | HQL |
|---|---|---|
| Price | $7.64 | $16.61 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 319.3K | 120.9K |
| Earning Date | 11-20-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.56% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.79 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $17.08 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.30 | $11.34 |
| 52 Week High | $7.89 | $14.37 |
Technical Indicators
Market Signals| Indicator | DRTS | HQL |
|---|---|---|
| Relative Strength Index (RSI) | 78.12 | 45.24 |
| Support Level | $6.45 | $16.40 |
| Resistance Level | $5.14 | $17.29 |
| Average True Range (ATR) | 0.50 | 0.38 |
| MACD | 0.20 | -0.02 |
| Stochastic Oscillator | 92.04 | 42.92 |
Price Performance
Historical ComparisonAbout DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.